Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. PINS
4. COIN
5. RDDT
6. FSLR
7. SYK
8. SBUX
9. MA
10. FND

Go back to Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02

Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results

March 12, 2020 8:05 AM EDT

CARMIEL, Israel, March 12, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fourth quarter and full year ended December 31, 2019, and provided a business update on recent corporate and clinical developments. The Company will discuss the clinical, corporate and financial highlights on a conference call and live webcast, scheduled for Thursday, March 12th,... More